ArticleInternational journal of nanomedicine2022
Oral Delivery of Pterostilbene by L-Arginine-Mediated "Nano-Bomb" Carrier for the Treatment of Ulcerative Colitis.
Article in International journal of nanomedicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 48 citations in OpenAlex.
- Advances of oral micro- and nanomedicines for modulating intestinal barriers in the treatment of intestinal diseases.Acta pharmaceutica Sinica. B · 2026Review
- Advanced Targeted Curcumin Delivery Using Spatiotemporally Controlled Nanohybrid Polysaccharide-Based Hydrogel for Ulcerative Colitis Therapy.Gels (Basel, Switzerland) · 2026Article
- Dietary L-arginine supplementation exerts preventive effects on colitis through modulation of the gut microbiota.Frontiers in nutrition · 2026Article
- EUK nanozyme-loaded PL&GA coacervate droplets attenuate ulcerative colitis through restoring gut homeostasis and restricting intestinal cell ferroptosis.Materials today. Bio · 2025Article
- Sodium alginate-hyaluronic acid composite particles for doxorubicin delivery: in vitro characterization and cytotoxicity evaluation.BMC research notes · 2025Article
- Applications of Antioxidant Nanoparticles in Immune-Mediated Inflammatory Diseases.Antioxidants (Basel, Switzerland) · 2025Review
- Article
- A targeted and synergetic nano-delivery system againstMaterials today. Bio · 2025Article
- Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics.Drug delivery · 2024Review
- Pterostilbene: a potential therapeutic agent for fibrotic diseases.Inflammopharmacology · 2024Review
- Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.Pharmaceutics · 2024Review
- Dual-Sensitive Carbohydrate-Based Nanosystem for Targeted Drug Delivery to Potentiate the Therapeutic Efficacy of Ulcerative Colitis.International journal of nanomedicine · 2024Article
- Oral Administration of Platinum Nanoparticles with SOD/CAT Cascade Catalytic Activity to Alleviate Ulcerative Colitis.Journal of functional biomaterials · 2023Article
- Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease.Journal of nanobiotechnology · 2023Article
- Increased brain uptake of pterostilbene loaded folate modified micellar delivery system.Drug delivery · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUlcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) of unknown aetiology affecting the colon and rectum. Pterostilbene (PS) has been reported as an effective antioxidant and anti-inflammatory agent in preclinical IBD models. However, the therapeutic outcomes of PS are limited by potential side effects associated with the systemic exposure and the modest bioavailability afforded by its oral administration. These issues can be improved with the use of intelligent responsive nanoparticles with the ability of lysosome escape, given their high drug delivery capacity and reducing the side effects. MATERIALS AND
methodsHerein, the hyaluronic acid (HA)-modified L-arginine CO
resultsHA-L-Arg-CO
conclusionThis pH-activated "nano-bomb" carrier with therapeutic effect can be exploited as efficient oral drug carriers for UC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.